LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.
The study will be divided into a 70-subject pre-study followed by a 200-subject clinical study, evaluating the use of Angle's ParsortixTM and HyCEADTM Ziplex platforms as a simple blood test to detect the presence of ovarian cancer.
The study is expected to complete in the first quarter of 2020.
The test has the potential to improve patient outcomes while also reducing overall healthcare costs.
Once the data from the study is available, Angle intends to use it to hold discussions with clinical laboratories and women's health companies to secure a partner for clinical deployment.
Angle shares were trading up 1.1% at 55.10 pence each on Thursday.
Angle (AGL)